# COVID19 vaccine type and humoral immune response in patients receiving dialysis

# **Table of Contents**

Supplemental Methods	p2	
Supplemental Table 1 Characteristics of patients on dialysis by vaccine type	p3	

## **Supplemental Methods**

### **Assay Characteristics**

The Siemens total RBD Ig assay measures IgG and IgM antibodies. This assay is reported by the manufacture to have 100% sensitivity and 99.8% specificity for tests performed  $\geq$ 14 days after a positive reverse transcriptase polymerase chain reaction test<sup>1</sup>; it has been validated independently with similar performance characteristics<sup>2, 3</sup>. We used one of two Siemens RBD IgG assays, which are semiquantitative two-step sandwich indirect chemiluminescent assay with a manufacturer reported 95.6% (95% CI: 92.2-97.8%) sensitivity and 99.9% (95% CI 99.6-99.9%) specificity for tests performed  $\geq$ 21 days post positive reverse transcriptase polymerase chain reaction test. An index value  $\geq$ 1.0 is considered reactive. The two assays are compatible using a conversion factor, but one has a larger maximal index value range (>44 versus > 150).

We classified responses as absent total RBD Ig antibody, absent semiquantitative IgG antibody (index value <1), diminished antibody (semiquantitative IgG index value <10), or medium to high antibody  $(\geq 10)^4$ . We chose index value  $\geq 10$  as a cut-point based on a Siemens study (n=74) evaluating correlation with plaque reduction neutralization test which reported index values  $\geq 10$  had a positive predictive value of 100% for plaque reduction neutralization test50 >1:80.

### REFERENCES

1. U.S. Food & Drug Administration. *EUA Authorized Serology Test Performance*. 2020. Accessed June 28, 2021. <u>https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance</u>

2. Schnurra C, Reiners N, Biemann R, Kaiser T, Trawinski H, Jassoy C. Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests. *J Clin Virol*. Aug 2020;129:104544. doi:10.1016/j.jcv.2020.104544

3. Public Health England. *Evaluation of sensitivity and specificity of 4 commercially available SARS-CoV-2 antibody immunoassays.* . 2020. Accessed June 6, 2021.

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\_data/file/89 8437/Evaluation\_\_of\_sensitivity\_and\_specificity\_of\_4\_commercially\_available\_SARS-CoV-2\_antibody\_immunoassays.pdf

4. Anand S, Montez-Rath ME, Han J, et al. Serial SARS-CoV-2 Receptor-Binding Domain Antibody Responses in Patients Receiving Dialysis. *Ann Intern Med*. May 18 2021;doi:10.7326/M21-0256

	Overall	mRNA1273	BNT162b2	Ad26.COV2.S
Patient characteristics	N=2099	N=1316	N=416	N=367
Age				
18-44	180 (8)	87 (7)	36 (9)	57 (16)
45-64	685 (33)	365 (28)	106 (25)	214 (58)
65-79	885 (42)	606 (46)	195 (47)	84 (23)
≥80	349 (17)	258 (20)	79 (19)	12 (3)
Gender				
М	1277 (61)	792 (60)	264 (63)	221 (60)
F	822 (39)	524 (40)	152 (37)	146 (40)
<b>Race and Ethnicity</b>				
Hispanic	721 (34)	406 (31)	165 (40)	150 (41)
Non-Hispanic white	522 (25)	316 (24)	109 (26)	97 (26)
Non-Hispanic Black	209 (10)	81 (6)	28 (7)	100 (27)
Asian	312 (15)	263 (20)	42 (10)	7 (2)
Other	61 (3)	49 (4)	9 (2)	3 (1)
Missing	274 (13)	201 (15)	63 (15)	10 (3)
Geographic region				
South	464 (22)	73 (6)	38 (9)	353 (96)
West	1635 (78)	1243 (94)	378 (91)	14 (4)
Dialysis Modality				
Hemodialysis	1176 (84)	1111 (85)	354 (85)	311 (85)
CCPD	266 (13)	176 (13)	49 (12)	41 (11)
CAPD	25 (1)	18 (1)	2(1)	5 (1)
Home Hemodialysis	32 (2)	11 (1)	11 (2)	10 (3)
ESKD Vintage (years)				
< 2	799 (38)	506 (38)	173 (42)	120 (33)
2 - 5	726 (35)	455 (35)	143 (34)	128 (35)
$\geq$ 5	574 (27)	355 (27)	100 (24)	119 (32)
Diabetes				
Yes	1350 (64)	848 (64)	258 (62)	244 (66)
No	749 (36)	464 (36)	158 (38)	123 (34)
RBD antibody status prio	r to vaccine^			
Seropositive	696 (33)	361 (27)	141 (34)	194 (53)
Seronegative	1403 (67)	955 (73)	275 (66)	173 (47)

Supplemental Table 1 Characteristics of patients on dialysis by vaccine type

Abbreviations: CCPD, continuous cycler-assisted peritoneal dialysis; CAPD, continuous automated peritoneal dialysis; ESKD, end-stage kidney disease; RBD, receptor-binding domain; ^seropositive prior to vaccination indicates likely SARS-CoV-2 infection prior to vaccination